

# Year-end report

## 1 January – 31 December 2013



- Net sales rose to SEK 479.4 M (433.8), up approximately 12%.\* Order bookings totalled SEK 460.5 M (447.6), up about 4%.\*
- Operating profit amounted to SEK 48.0 M (18.1). The improvement was attributable to the Medical Technology business area. A positive volume trend, combined with implemented measures, created a stable earnings trend.
- Profit after financial items amounted to SEK 41.6 M (8.6). Net financial items were impacted by positive exchange-rate differences of SEK 0.4 M (negative: 1.5).
- Profit after tax totalled SEK 32.6 M (8.2), corresponding to SEK 5.39 (1.35) per share before dilution.
- Cash flow after investments improved to SEK 66.9 M (neg: -2.0).
- The Board of Directors proposes a dividend of SEK 2.00 (1.00) per share to be paid.

### President Göran Brorsson's comments:

"We have experienced a positive trend in 2013. Sales and profits have improved. A healthy EBITDA margin combined with a reduction in working capital and lower investments have resulted in a very healthy cash flow from operations. The positive trend creates conditions for a proposed dividend of SEK 2.00 per share."

In the Medical Technology business area, we increased our market share and exceeded our growth target of 10%. During the year, we implemented a number of substantial efficiency enhancements, primarily involving production. Altogether, this resulted in sharply improved profitability. The focus in 2014 is on continued streamlining and further development of our cooperation with both existing and new customers. The marketing organisation has been strengthened to enable this.

In the Metrology business area, the latter part of the year was marked by cautiousness among our customers. During the first quarter, we had some problems with quality related to the introduction of new products, which were resolved in their entirety during the first half-year. Since the market has reacted positively to the performance of the new products, we are confident about the volume trend in 2014 and anticipate a volume increase during the year."

	Oct–Dec 2013	Oct–Dec 2012	Jan–Dec 2013	Jan–Dec 2012
Order bookings, SEK M	104.2	120.9	460.5	447.6
Net sales, SEK M	119.4	124.3	479.4	433.8
Growth, %*	-2.1	8.6	11.8	4.3
EBITDA, SEK M	22.4	19.1	88.6	54.3
EBITDA, %	18.8	15.4	18.5	12.5
Operating profit, SEK M	12.3	10.4	48.0	18.1
Operating margin, %	10.3	8.4	10.0	4.2
Profit after financial items, SEK M	11.1	9.1	41.6	8.6
Profit after tax, SEK M	8.4	9.0	32.6	8.2
Earnings per share before dilution, SEK	1.39	1.49	5.39	1.35

\* Adjusted for exchange-rate fluctuations during the year.

### Elos AB (publ)

Corp. Reg. No. 556021-9650  
Nya Stadens Torg 10  
SE-531 31 Lidköping, Sweden

Tel: +46 (0)510 48 43 60  
Fax: +46 (0)510 680 04  
www.elos.se

### **Operations in general**

The Group operates in two business areas – Medical Technology and Metrology – with the emphasis on Medical Technology. After a few years of major investments, the focus is now on sales growth and higher efficiency.

### **Invoicing and earnings October – December 2013**

The Group's net sales during the quarter decreased to SEK 119.4 M (124.3). Adjusted for exchange-rate fluctuations, net sales decreased by 2.1%. Order bookings decreased to SEK 104.2 M (120.9). Adjusted for exchange-rate fluctuations, order bookings decreased 13.5%. Net sales increased for the Medical Technology business area and declined for the Metrology business area. Order bookings declined for both of the Group's business areas.

Operating profit improved to SEK 12.3 M (10.4), corresponding to an operating margin of 10.3% (8.4). The Medical Technology business area reported a significant improvement in profit during the quarter, generated by the effects of implemented measures and a positive volume trend. Operating profit for the Metrology business area was adversely impacted by low volumes and increased development costs.

The Group's net financial items were positively impacted by exchange-rate differences of SEK 0.4 M (0.3) and amounted to an expense of SEK 1.2 M (expense: 1.3). Profit after financial items amounted to SEK 11.1 M (9.1).

Profit after tax totalled SEK 8.4 M (9.0), corresponding to SEK 1.39 (1.49) per share before dilution. The Group's comprehensive income was SEK 10.8 M (10.3). Comprehensive income per share before dilution amounted to SEK 1.79 (1.70).

Cash flow from operating activities improved to SEK 26.0 M (24.6). Cash flow after investments improved to SEK 19.4 M (19.1).

The comparative figures for the fourth quarter of 2012 affected by the amendment of IAS 19R, the accounting policy for pensions, have been adjusted.

### **Invoicing and earnings January – December 2013**

The Group's net sales rose during the year to SEK 479.4 M (433.8). Adjusted for exchange-rate fluctuations, the increase was 11.8%. Order bookings amounted to SEK 460.5 M (447.6). Adjusted for exchange-rate fluctuations, the increase was 3.8%. Net sales increased for both of the Group's business areas. Order bookings increased for the Medical Technology business area and declined for the Metrology business area.

Operating profit improved during the year to SEK 48.0 M (18.1). The improvement was attributable to the Medical Technology business area. A positive volume trend, combined with implemented measures, created a stable earnings trend.

The Group's net financial items were positively impacted by exchange-rate differences of SEK 0.4 M (expense: 1.5) and amounted to an expense of SEK 6.4 M (expense: 9.5). Profit after financial items was SEK 41.6 M (8.6).

Profit after tax totalled SEK 32.6 M (8.2), corresponding to SEK 5.39 (1.35) per share before dilution. The Group's comprehensive income was SEK 37.0 M (4.7). Comprehensive income per share before dilution amounted to SEK 6.11 (0.77).

Cash flow from operating activities improved to SEK 87.3 M (39.5). Cash flow after investments improved to SEK 66.9 M (neg: 2.0). The improvement was primarily due to better earnings and a lower investment rate.

The comparative figures for the fourth quarter of 2012 affected by the amendment of IAS 19R, the accounting policy for pensions, have been adjusted.

### **Medical Technology**

The business area is one of Europe's leading partners in the development and production of precision products used in medical technology and components, such as dental and orthopaedic implants and instruments. The business area is collectively marketed as Elos Medtech and has operations in Sweden, Denmark and China. Customers consist primarily of internationally active medical-technology companies in the following market segments: Dental, Orthopaedics, Medical Devices and Diagnostics.

	<b>Oct–Dec</b>	Oct–Dec	<b>Jan–Dec</b>	Jan–Dec
SEK M	<b>2013</b>	2012	<b>2013</b>	2012
Order bookings, SEK M	<b>82.9</b>	87.9	<b>356.5</b>	338.2
Net sales, SEK M	<b>96.5</b>	92.2	<b>368.1</b>	327.3
Growth, %*	<b>5.4</b>	9.6	<b>13.9</b>	10.2
EBITDA, SEK M	<b>20.3</b>	9.2	<b>70.7</b>	28.6
EBITDA, %	<b>21.0</b>	10.0	<b>19.2</b>	8.7
Operating profit, SEK M	<b>11.7</b>	1.6	<b>36.4</b>	-2.8
Operating margin, %	<b>12.1</b>	1.7	<b>9.9</b>	-0.9

The demand trend of our customers in the Medical Technology business area was impacted by the global economic trend. This was particularly evident in regions where the patient pays personally for a significant share of the cost. In our largest segment, Dental, a positive trend can be discerned. In the Orthopaedics segment, the Trauma and Spine areas showed continued growth. In the Medical Devices segment, the diabetes market continued to display stable growth, while the area for hearing aids experienced weak overall growth, with the exception of certain niche markets. The Diagnostics segment continued to report healthy growth.

Following extensive investments in the years 2010–2012, the focus is now on developing the business area's customer base. During the year, the market organisation was strengthened in order to intensify efforts to expand the customer base and capitalise on growth opportunities. The establishment in Tianjin, which is part of the Group's geographic growth strategy, serves as a base for deliveries to the Group's medical-technology customers, who are now establishing themselves in the Chinese market. Work is also in progress to introduce new customers in Tianjin. In addition to a sharpened market focus, priority is also being assigned to the development of the service offering, in part in the form of shorter delivery times from production. This will create opportunities to offer our customers improved conditions for meeting variations in demand.

The Group's strategy in the business area is to develop proprietary products that complement our customers' product range, such as various types of instruments. The introduction of these products, which have been launched in recent years, took longer than anticipated. Growth during the year was about 40%. Proprietary products now account for slightly more than 6% (5) of the business area's net sales.

Net sales totalled SEK 368.1 M (327.3) which, adjusted for exchange-rate fluctuations, corresponded to an increase of 13.9%. Order bookings amounted to SEK 356.5 M (338.2), corresponding to growth of 6.6% adjusted for exchange-rate fluctuations. The lower rise in order bookings in relation to sales was due to the Group's customers increasingly changing their order patterns from orders based on previous years/periods to a forecast-based delivery-request system, which is more efficient for both parties. Operating profit improved to SEK 36.4 M (loss: 2.8), corresponding to an operating margin of 9.9% (neg: 0.9). The earnings improvement was primarily attributable to the positive volume trend, combined with the improvement measures implemented, particularly at the facility in Timmersdala.

### **Metrology**

The business area consists of Elos Fixturlaser, which develops, manufactures and markets laser-based alignment and positioning systems. The company is regarded as a market leader in its segment, with a global market share of about 30%. Products are primarily sold through a worldwide network of distributors.

	<b>Oct–Dec</b>	Oct–Dec	<b>Jan–Dec</b>	Jan–Dec
SEK M	<b>2013</b>	2012	<b>2013</b>	2012
Order bookings, SEK M	<b>21.3</b>	33.0	<b>104.0</b>	109.3
Net sales, SEK M	<b>22.9</b>	32.1	<b>111.3</b>	106.5
Growth, %	<b>-28.7</b>	5.9	<b>4.5</b>	-10.2
EBITDA, SEK M	<b>3.9</b>	10.7	<b>24.9</b>	30.3
EBITDA, %	<b>17.0</b>	33.3	<b>22.4</b>	28.4
Operating profit, SEK M	<b>2.9</b>	10.3	<b>20.8</b>	27.4
Operating margin, %	<b>12.7</b>	32.1	<b>18.7</b>	25.7

Although the trend in the wind-power segment was positive, but demand for the business area's products gradually declined in the latter half of the year. The trend in North America remained positive despite diminishing growth toward the end of the year. Other markets have trended weakly.

The introduction of Fixturlaser NXA, which was implemented during the first six months of the year, was troubled by initial quality problems that were resolved during the first half of the year. Fixturlaser NXA Ultimate was introduced in late November and is currently the most advanced system in the NXA family. Market response to the NXA system is favourable. Fixturlaser NXA was nominated to the Product of the Year competition, hosted by the US industry magazine Plant Engineering.

During the year, additional development efforts were made in order to further strengthen the company's market position as a supplier of the most innovative and user-friendly product range in the metrology business area for alignment systems for rotating machinery. These efforts will result in new product introductions in 2014.

Net sales for the business area amounted to SEK 111.3 M (106.5), corresponding to an increase of 4.5%. Order bookings totalled SEK 104.0 M (109.3), a decline of 4.9%. Operating profit was SEK 20.8 M (27.4). The lower operating profit was primarily due to increased development costs during the year. During the second quarter, costs of SEK 1.3 M from initial quality problems pertaining to the newly developed product, Fixturlaser NXA, were charged against earnings. During the fourth quarter, compensation for these quality problems was obtained from suppliers and had a positive impact of SEK 1.5 M on profit. The operating margin was 18.7% (25.7).

### **Investments**

Following several years of major investments, the rate of investment was reduced in 2013. The Group's investments in buildings, land, machinery and equipment amounted to SEK 10.1 M (35.1). In addition, SEK 9.2 M (13.1) was invested in capitalised development expenditure and SEK 5.4 M (3.0) in other intangible fixed assets.

### **Financial position and liquidity**

The Group's total assets during the year declined SEK 8.7 M to SEK 530.4 M (539.1).

The Group's shareholders' equity amounted to SEK 232.8 M (201.9). Shareholders' equity per share was SEK 38.48 (33.37). Risk-bearing equity at year-end totalled SEK 258.3 M (228.8), corresponding to 48.7% (42.4) of total capital. The Group's equity/assets ratio was 43.9% (37.5).

The Group's cash flow from operating activities improved to SEK 87.3 M (39.5). Cash flow after investments and sales of fixed assets amounted to SEK 66.9 M (neg: 2.0).

The Group's net borrowing decreased during the period to SEK 172.6 M (223.8).

The Group's cash and cash equivalents, including unutilised overdraft facilities, amounted to SEK 76.1 M (61.7).

The comparative figures for the fourth quarter of 2012 affected by the amendment of IAS 19R, the accounting policy for pensions, have been adjusted.

### **Personnel**

At the end of the year, the Group had 419 (429) full-time employees.

### **Outlook 2014**

The improved market position of the Medical Technology business area creates positive conditions for further growth in 2014.

In the Metrology business area, the new NXA system together with next coming product launches is expected to generate a positive volume trend in 2014.

### **Dividend**

The Board of Directors proposes that a dividend of SEK 2.00 (1.00) per share be paid for the 2013 fiscal year. In accordance with the motion, the share dividend will total SEK 12.1 M (6.1).

### **Convertible debentures program**

The Annual General Meeting of Elos AB on 3 May 2011 approved the Board's motion to issue convertible debentures in a nominal maximum amount of SEK 13,500,000, which can be converted into Class B shares. Employees of the Elos Group subscribed for Elos 2011/2014 convertible debentures totalling SEK 10,999,000, corresponding to 129,400 convertible debentures at a conversion price of SEK 85. Further information about the programme is available at Elos' website under Financial information/Corporate Governance/Incentive scheme.

### **Parent Company**

In addition to central management issues, the Parent Company provides Group-wide support activities, such as market support, finance and financial control.

The Parent Company's net sales totalled SEK 10.0 M (9.6). Profit after financial items amounted to SEK 16.5 M (loss: 1.6), including Group contributions of SEK 25.0 M (4.0). The Group's comprehensive income was SEK 8.9 M (2.4).

The percentage of risk-bearing capital was 83.1% (78.5). The equity/assets ratio was 82.6% (78.3). The Parent Company's cash and cash equivalents, including unutilised overdraft facilities, amounted to SEK 56.9 M (42.9).

### **Significant risks and uncertainties**

The Group's significant risks and uncertainties include business risks associated with customers and suppliers, and other external factors, such as risks related to the prices of input goods. Financial risks also arise in conjunction with fluctuations in exchange and interest rates. A detailed description of the Group's risks and uncertainties, and how they are managed, is presented in the Board of Directors' Report in the 2012 Annual Report.

### **Related-party transactions**

The company has no ongoing transactions with related parties.

### **Accounting policies**

The consolidated financial statements for 2013, similar to the year-end accounts for 2012, were prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU and with the Swedish Annual Accounts Act. The Parent Company's accounts were prepared in accordance with the Annual Accounts Act and recommendation RFR 2 Reporting for Legal Entities, issued by the Swedish Financial Reporting Board.

This interim report was prepared in accordance with IAS 34. The term "IFRS" in this document includes application of both IAS and IFRS standards, as well as interpretations of these standards as published by the IASB's Standards Interpretation Committee (SIC) and the International Financial Reporting Interpretations Committee (IFRIC).

The Group applies the same accounting policies as those described in the 2012 Annual Report. With the exception of the revised version of IAS 19R, no new or revised recommendations with application as of 2013 were considered to have had any significant impact on the financial statements.

#### *Impact of revised IAS 19R*

The revised version of IAS 19R represents a change of accounting policies in accordance with IAS 8 and is to be applied to fiscal years commencing 1 January 2013 or later. This entails that information about the change of accounting policies be included in interim reports, in accordance with IAS 34, paragraph 16A.

The opening balance on 1 January 2012 has been restated due to the retroactive impact of the new accounting policies on financial statements. Consequently, the comparative figures for the quarters and the full-year 2012 have been adjusted. The transition to the new accounting policies resulted in an increase of SEK 12.6 M in net pension provisions, including special employer's contributions, on 1 January 2012. The deficit on the transition date was charged against retained earnings, meaning under shareholders' equity, entailing a reduction of SEK 9.9 M in consolidated shareholders' equity on 1 January 2012, taking into account deferred taxes.

The comparative data at 31 December 2012 shows an increase of SEK 15.4 M in net pension provisions including special employer's contributions, an increase of SEK 3.4 M in deferred tax assets and a reduction of SEK 12.0 M in shareholders' equity. The Group's other comprehensive income declined SEK 2.1 M, which also entailed a reduction of SEK 0.34 in comprehensive income per share.

## **Other**

Changed interest rates resulted in the use of a new assumption in the calculation of pension liabilities in accordance with IAS 19R, which meant that the items for the period recognised under other comprehensive income were impacted by an actuarial gain of SEK 3.3 M, including tax.

## **Annual General Meeting**

The next Annual General Meeting (AGM) will be held in Lidköping, on 29 April 2014.

## **Nomination committee**

At the 2013 AGM, it was resolved that the Nomination Committee was to comprise one representative for each of the three largest shareholders – in terms of votes on 30 September every year – and one representative for other shareholders. The task of the Nomination Committee ahead of the 2014 AGM is to submit proposals concerning the nomination of the Chairman of the AGM, the Chairman of the Board, the number of Board members and election of Board members and, wherever appropriate, the election of an auditor and resolutions concerning Board fees, remuneration for Committee work and auditors' fees.

The Nomination Committee ahead of the 2014 AGM comprises Agneta Bengtsson Runmarker, Bo Nilsson and Thomas Öster as representatives of the three largest shareholders and Bengt Belfrage as representative of other shareholders. The Chairman is Bengt Belfrage.

## **Auditor's review**

This year-end report has not been reviewed by the company's auditor.

## **Annual Report**

Elos' annual report is scheduled to be completed at the end of March 2014 and will be available at the company and on Elos' website, [www.elos.se](http://www.elos.se). Printed Annual Reports will also be sent to shareholders who, according to Euroclear, wish to receive company information.

## **Financial information 2014**

The interim report for January-March 2014 will be published on 29 April 2014.

The interim report for January-June 2014 will be published on 22 August 2014.

The interim report for January-September 2014 will be published on 24 October 2014.

Lidköping, 21 February 2014

Elos AB (publ)

The Board of Directors

## **For further information, please contact:**

Göran Brorsson, President and CEO, +46 (0)510-48 43 65, +46 (0)705-11 78 60, e-mail: [goran.brorsson@elos.se](mailto:goran.brorsson@elos.se)

Ulrica Ehn, CFO, +46 (0)510-48 43 67, +46 (0)702-72 11 61, e-mail: [ulrica.ehn@elos.se](mailto:ulrica.ehn@elos.se)

The information in this year-end report is such that Elos AB (publ) must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

The information was issued for publication on 21 February 2014 at 8:00 a.m. (CET).

**CONSOLIDATED INCOME STATEMENT AND  
STATEMENT OF COMPREHENSIVE INCOME**

SEK M	Oct-Dec 2013	Oct-Dec 2012 *	Jan-Dec 2013	Jan-Dec 2012 *
Net sales	119,4	124,3	479,4	433,8
Cost of goods sold	-79,2	-87,9	-319,6	-314,2
<b>Gross profit</b>	<b>40,2</b>	36,4	<b>159,8</b>	119,6
Selling expenses	-9,2	-9,5	-36,9	-38,0
Administration expenses	-13,1	-12,5	-52,8	-50,3
Development expenses	-7,8	-3,5	-23,2	-13,8
Other operating income/expenses	2,2	-0,5	1,1	0,6
<b>Operating profit</b>	<b>12,3</b>	10,4	<b>48,0</b>	18,1
Financial income	0,1	0,1	0,4	0,2
Financial expenses	-1,7	-1,7	-7,2	-8,2
Exchange-rate differences	0,4	0,3	0,4	-1,5
<b>Result after financial items</b>	<b>11,1</b>	9,1	<b>41,6</b>	8,6
Taxes	-2,7	-0,1	-9,0	-0,4
<b>Net profit after taxes</b>	<b>8,4</b>	9,0	<b>32,6</b>	8,2
<b>Profit attributable to:</b>				
Parent company shareholders	8,4	9,0	32,6	8,2
<b>STATEMENTS OF COMPREHENSIVE INCOME</b>				
<b>Result after financial items</b>	<b>8,4</b>	9,0	<b>32,6</b>	8,2
<b>Other comprehensive income</b>				
<b>Items that will not be reclassified to the income statement</b>				
Actuarial gains and losses	0,2	-0,7	2,9	-2,7
Taxes	0,0	0,1	-0,6	0,6
	<b>0,2</b>	-0,6	<b>2,3</b>	-2,1
<b>Items that may be reclassified to the income statement</b>				
Translation differences	4,1	2,7	4,5	-5,5
Hedging of net investments	-2,3	-1,1	-2,9	5,3
Taxes	0,4	0,3	0,5	-1,2
	<b>2,2</b>	1,9	<b>2,1</b>	-1,4
<b>Other comprehensive income, net</b>	<b>2,4</b>	1,3	<b>4,4</b>	-3,5
<b>Comprehensive income for the period</b>	<b>10,8</b>	10,3	<b>37,0</b>	4,7
<b>Comprehensive income attributable to:</b>				
Parent company shareholders	10,8	10,3	37,0	4,7
EBITDA	18,8%	15,4%	18,5%	12,5%
EBIT	10,3%	8,4%	10,0%	4,2%
Depreciation charged against earnings	10,1	8,7	40,6	36,2
Earnings after taxes per share (SEK), before dilution	1:39	1:49	5:39	1:35
Earnings after taxes per share (SEK), after dilution **	1:36	1:49	5:32	1:35
Number of shares (thousands) before dilution	6 051	6 051	6 051	6 051
Number of shares (thousands) after dilution**	6 180	6 180	6 180	6 180
Number of shares (thousands) end of period	6 051	6 051	6 051	6 051

\* Comparative figures for 2012 have been adjusted due to an amendment to IAS 19R, the accounting policy for pension.

\*\* Attributable to parent company shareholders' share of the income after tax. Considerations to convertibles issued 2011-07-01.

## CONDENSED CONSOLIDATED BALANCE SHEET

SEK M	2013-12-31	2012-12-31 *
<b>Assets</b>		
Intangible fixed assets	81,0	70,3
Tangible fixed assets	218,2	241,1
Financial fixed assets	4,8	10,4
Other current assets	195,2	193,8
Cash and bank balances	31,2	23,5
<b>Total assets</b>	<b>530,4</b>	539,1
<b>Shareholders' equity and liabilities</b>		
Shareholders' equity	232,8	201,9
Long-term liabilities	167,2	202,6
Current liabilities	130,4	134,6
<b>Total shareholders' equity and liabilities</b>	<b>530,4</b>	539,1
<b>Pledged assets</b>	<b>166,5</b>	178,7
<b>Contingent liabilities</b>	<b>0,4</b>	0,4

## KEY FIGURES

		Jan-Dec 2013	Jan-Dec 2012 *
Return on operating capital	%	11,7	4,4
Return on shareholders' equity	%	15,0	3,9
Share of risk-bearing capital	%	48,7	42,4
Equity/assets ratio	%	43,9	37,5
Net debt	SEK M	172,6	223,8
Investments excluding shares	SEK M	24,7	51,2
Average number of employees		424	424
Shareholders' equity per share	SEK	38:48	33:37
Dividends (proposal 2013)	SEK	2:00	1:00

## CHANGES IN SHAREHOLDERS' EQUITY

SEK M	31 Dec 2013	31 Dec 2012 *
Opening balance	201,9	216,2
Change of accounting policy	-	-9,9
Adjusted opening balance	201,9	206,3
Dividends	-6,1	-9,1
Comprehensive income for the period	37,0	4,7
<b>Closing balance, shareholders' equity</b>	<b>232,8</b>	201,9

\* Comparative figures for 2012 have been adjusted due to an amendment to IAS 19R, the accounting policy for pension.



## CONSOLIDATED CASH FLOW STATEMENT

SEK M	Oct-Dec 2013	Oct-Dec 2012	Jan-Dec 2013	Jan-Dec 2012
Profit after net financial items	11,1	9,1	41,6	8,6
Reversal of depreciation	10,1	8,7	40,6	36,2
Adjustment items	1,0	-2,3	2,7	0,1
Income tax paid	0,6	4,2	-2,8	0,1
Change in working capital	3,2	4,9	5,2	-5,5
<b>Cash flow from operations</b>	<b>26,0</b>	<b>24,6</b>	<b>87,3</b>	<b>39,5</b>
Investments in fixed assets	-6,5	-6,0	-21,3	-42,0
Sales of fixed assets	-0,1	0,5	0,9	0,5
<b>Balance after investments in fixed assets</b>	<b>19,4</b>	<b>19,1</b>	<b>66,9</b>	<b>-2,0</b>
Change in interest bearing liabilities	-4,0	-2,7	-6,5	4,9
New long-term loans	-	-	-	21,6
Amortization of long-term loans	-7,9	-12,2	-42,6	-27,1
Realized financial exchange-rate differences	-2,5	4,1	-4,3	5,9
Dividends	0,0	0,0	-6,1	-9,1
<b>Cash flow for the year</b>	<b>5,0</b>	<b>8,3</b>	<b>7,4</b>	<b>-5,8</b>
Liquid funds at beginning of the year	25,9	15,3	23,5	29,8
Exchanges-rate differences in liquid funds	0,3	-0,1	0,3	-0,5
<b>Liquid funds at end of the period</b>	<b>31,2</b>	<b>23,5</b>	<b>31,2</b>	<b>23,5</b>

## NET SALES AND OPERATING PROFIT/LOSS PER BUSINESS AREA

Net sales	Oct-Dec 2013	Oct-Dec 2012	Jan-Dec 2013	Jan-Dec 2012
SEK M				
Medical Technology	96,5	92,2	368,1	327,3
Metrology	22,9	32,1	111,3	106,5
Other	0,0	0,0	0,0	0,0
<b>Total net sales</b>	<b>119,4</b>	<b>124,3</b>	<b>479,4</b>	<b>433,8</b>

Operating profit/loss	Oct-Dec 2013	Oct-Dec 2012	Jan-Dec 2013	Jan-Dec 2012
SEK M				
Medical Technology	11,7	1,6	36,4	-2,8
Metrology	2,9	10,3	20,8	27,4
Other	-2,3	-1,5	-9,2	-6,5
<b>Total operating profit/loss</b>	<b>12,3</b>	<b>10,4</b>	<b>48,0</b>	<b>18,1</b>

## QUARTERLY FIGURES - GROUP

	Q 4	Q 3	Q 2	Q 1	Q 4	Q 3	Q 2	Q 1
SEK M	2013	2013	2013	2013	2012	2012	2012	2012
Net sales	119,4	112,5	129,4	118,1	124,3	99,7	109,7	100,1
Cost of goods sold	-79,2	-75,3	-86,2	-78,9	-87,9	-70,8	-83,5	-72,0
<b>Gross profit</b>	<b>40,2</b>	<b>37,2</b>	<b>43,2</b>	<b>39,2</b>	<b>36,4</b>	<b>28,9</b>	<b>26,2</b>	<b>28,1</b>
Selling adm.and developm.exp.	-30,1	-25,6	-30,5	-26,7	-25,5	-22,6	-27,2	-26,7
Other operating items	2,2	-1,2	-0,4	0,5	-0,5	-2,1	0,7	2,5
<b>Operating profit/loss</b>	<b>12,3</b>	<b>10,4</b>	<b>12,3</b>	<b>13,0</b>	<b>10,4</b>	<b>4,2</b>	<b>-0,3</b>	<b>3,9</b>
Net financial items	-1,6	-1,6	-1,7	-1,9	-1,6	-2,1	-2,0	-2,3
Exchange-rate differences	0,4	-1,3	1,5	-0,2	0,3	-2,4	2,1	-1,5
<b>Profit/loss after financial items</b>	<b>11,1</b>	<b>7,5</b>	<b>12,1</b>	<b>10,9</b>	<b>9,1</b>	<b>-0,3</b>	<b>-0,2</b>	<b>0,1</b>
<b>Taxes</b>	<b>-2,7</b>	<b>-1,6</b>	<b>-1,9</b>	<b>-2,8</b>	<b>-0,1</b>	<b>-0,2</b>	<b>0,0</b>	<b>-0,2</b>
<b>Profit/loss after taxes</b>	<b>8,4</b>	<b>5,9</b>	<b>10,2</b>	<b>8,1</b>	<b>9,0</b>	<b>-0,5</b>	<b>-0,2</b>	<b>-0,1</b>

## QUARTELY FIGURES - BUSINESS AREAS

Net sales	Q 4	Q 3	Q 2	Q 1	Q 4	Q 3	Q 2	Q 1
SEK M	2013	2013	2013	2013	2012	2012	2012	2012
Medical Technology	96,5	82,7	98,2	90,7	92,2	74,5	84,1	76,5
Metrology	22,9	29,8	31,2	27,4	32,1	25,2	25,6	23,6
Other	-	-	-	-	-	-	-	-
<b>Total</b>	<b>119,4</b>	<b>112,5</b>	<b>129,4</b>	<b>118,1</b>	<b>124,3</b>	<b>99,7</b>	<b>109,7</b>	<b>100,1</b>
<b>Operating profit/loss</b>	<b>Q 4</b>	<b>Q 3</b>	<b>Q 2</b>	<b>Q 1</b>	<b>Q 4</b>	<b>Q 3</b>	<b>Q 2</b>	<b>Q 1</b>
SEK M	2013	2013	2013	2013	2012	2012	2012	2012
Medical Technology	11,7	5,5	9,8	9,4	1,6	-1,5	-3,5	0,6
Metrology	2,9	7,0	4,8	6,1	10,3	6,7	5,8	4,6
Other	-2,3	-2,1	-2,3	-2,5	-1,5	-1,0	-2,6	-1,4
<b>Total</b>	<b>12,3</b>	<b>10,4</b>	<b>12,3</b>	<b>13,0</b>	<b>10,4</b>	<b>4,2</b>	<b>-0,3</b>	<b>3,8</b>

**PARENT COMPANY INCOME STATEMENT AND  
STATEMENTS OF COMPREHENSIVE INCOME**

SEK M	Oct-Dec 2013	Oct-Dec 2012	Jan-Dec 2013	Jan-Dec 2012
Net sales	2,5	2,4	10,0	9,6
Cost of goods sold	0,0	0,0	0,0	0,0
<b>Gross profit</b>	<b>2,5</b>	<b>2,4</b>	<b>10,0</b>	<b>9,6</b>
Administration expenses	-4,8	-3,5	-18,5	-15,3
Other operating income/expenses	-0,1	0,0	-0,1	0,0
<b>Operating profit</b>	<b>-2,4</b>	<b>-1,1</b>	<b>-8,6</b>	<b>-5,7</b>
Result fr. participations in group comp.	25,0	4,0	25,0	4,0
Financial income	0,3	0,5	1,2	2,2
Financial expenses	-0,3	-0,2	-1,1	-2,1
<b>Result after financial items</b>	<b>22,6</b>	<b>3,2</b>	<b>16,5</b>	<b>-1,6</b>
Appropriations	-3,0	-1,0	-3,0	-1,0
Taxes	-2,7	-0,6	-2,3	0,6
<b>Net profit after taxes</b>	<b>16,9</b>	<b>1,6</b>	<b>11,2</b>	<b>-2,0</b>

**Result attributable to:**

Parent company shareholders	16,9	1,6	11,2	-2,0
-----------------------------	------	-----	------	------

**STATEMENTS OF COMPREHENSIVE INCOME**

<b>Net profit after taxes</b>	<b>16,9</b>	<b>1,6</b>	<b>11,2</b>	<b>-2,0</b>
<b>Other comprehensive income</b>				
<b>Items that may be reclassified to the income statement</b>				
Hedging of net investment	-2,3	-1,2	-3,0	5,3
Tax	0,9	0,3	0,7	-0,9
<b>Other comprehensive income, net</b>	<b>-1,4</b>	<b>-0,9</b>	<b>-2,3</b>	<b>4,4</b>
<b>Comprehensive income for the period</b>	<b>15,5</b>	<b>0,7</b>	<b>8,9</b>	<b>2,4</b>
<b>Comprehensive income attributabel to:</b>				
Parent company shareholders	15,5	0,7	8,9	2,4

**CONDENSED PARENT COMPANY BALANCE SHEET**

SEK M	2013-12-31	2012-12-31
<b>Assets</b>		
Intangible fixed assets	5,8	3,4
Tangible fixed assets	0,2	0,5
Financial fixed assets	189,0	198,6
Other current assets	11,5	20,0
Cash and bank balances	16,9	6,6
<b>Total assets</b>	<b>223,4</b>	<b>229,1</b>
<b>Shareholders' equity and liabilities</b>		
Shareholders' equity	180,9	178,0
Untaxed reserves	4,7	1,7
Provisions	4,6	4,8
Long-term liabilities	2,9	14,9
Current liabilities	30,3	29,7
<b>Total shareholders' equity and liabilities</b>	<b>223,4</b>	<b>229,1</b>
<b>Pledged assets</b>	<b>2,0</b>	<b>2,0</b>
<b>Contingent liabilities</b>	<b>20,1</b>	<b>40,2</b>